Dos Santos Yuri de Albuquerque Pessoa, Park Viviane Flor, Cardozo Junior Luis Carlos Maia, Besen Bruno Adler Maccagnan Pinheiro, Mendes Pedro Vitale, Park Marcelo
Intensive Care Unit, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP, Brazil.
Laboratory of Medical Investigation (LIM-51), Emergency Discipline, University of São Paulo Medical School, São Paulo, SP, Brazil.
Intensive Care Med Exp. 2024 Feb 2;12(1):9. doi: 10.1186/s40635-024-00593-z.
Continuous renal replacement therapy (CRRT) support is crucial for critically ill patients and it is underexplored in specific situations. Experimental CRRT offers a means to gain insights into these scenarios, but the prohibitive cost of CRRT machines limits their accessibility. This study aimed to develop and validate a low-cost and precise dialysate controller for experimental CRRT.
Our results demonstrate a commendable level of precision in affluent flow control, with a robust correlation (R = 0.99) for continuous flow and a strong correlation (R = 0.95) for intermittent flow. Additionally, we observed acceptable agreement with a bias = 3.4 mL (upper limit 95% = 43.9 mL and lower limit 95% = - 37 mL) for continuous flow and bias = - 20.9 mL (upper limit 95% = 54 mL and lower limit 95% = - 95.7 mL) for intermittent flow, in this way, offering a precise CRRT dose for the subjects. Furthermore, we achieved excellent precision in the cumulative ultrafiltration net (UFnet), with a bias = - 2.8 mL (upper limit 95% = 6.5 mL and lower limit 95% = - 12 mL). These results remained consistent even at low affluent flow rates of 8, 12, and 20 mL/min, which are compatible with CRRT doses of 25-30 mL/kg for medium-sized animals. Moreover, the acceptable precision of our findings persisted when the dialysate controller was subjected to high filter dialysate chamber pressure for an extended duration, up to 797 min.
The low-cost dialysate controller developed and tested in this study offers a precise means of regulating CRRT in experimental settings. Its affordability and accuracy render it a valuable instrument for studying CRRT support in unconventional clinical scenarios, particularly in middle-income countries' experimental ICU laboratories.
持续肾脏替代疗法(CRRT)支持对危重症患者至关重要,且在特定情况下尚未得到充分研究。实验性CRRT提供了一种深入了解这些情况的方法,但CRRT机器高昂的成本限制了其可用性。本研究旨在开发并验证一种用于实验性CRRT的低成本、精确的透析液控制器。
我们的结果表明,在富液流控制方面具有值得称赞的精度水平,连续流的相关性很强(R = 0.99),间歇流的相关性也很强(R = 0.95)。此外,我们观察到连续流的偏差为3.4 mL(95%上限 = 43.9 mL,95%下限 = -37 mL),间歇流的偏差为 -20.9 mL(95%上限 = 54 mL,95%下限 = -95.7 mL),在此情况下为受试者提供了精确的CRRT剂量。此外,我们在累积超滤净量(UFnet)方面实现了出色的精度,偏差为 -2.8 mL(95%上限 = 6.5 mL,95%下限 = -12 mL)。即使在8、12和20 mL/min的低富液流率下,这些结果仍然一致,这些流率与中型动物25 - 30 mL/kg的CRRT剂量相符。此外,当透析液控制器在高滤器透析液腔压力下持续长达797分钟时,我们的研究结果仍保持可接受的精度。
本研究中开发并测试的低成本透析液控制器为在实验环境中调节CRRT提供了一种精确的方法。其可承受性和准确性使其成为研究非常规临床场景中CRRT支持的有价值工具,特别是在中等收入国家的实验ICU实验室中。